Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAS 102 · 1 trial · 2 indications
The number of participants who complete at least 2 cycles of iTTo for the treatment of advanced gastric and GEJ cancers, over the total duration of study.
Treatment related and non-related adverse events per CTCAE v.5.0 of iTTo for the treatment of advanced gastric and GEJ cancers. Incidence of adverse events, the number of dose modifications and discontinuations due to adverse events.
| Arm | Type | Description |
|---|---|---|
| Single Arm iTTO treatment | EXPERIMENTAL | Patients will receive the combination of irinotecan, TAS-102, and Oxaliplatin on a 28 day cycle with the following doses; * Irinotecan 160mg/m2 IV infusion over 60-90 mins on day 1 * Oxaliplatin 100mg/m2 IV infusion over 2 hours on day 1 * TAS-102 (Trifluridine/Tipiracil) 25mg/m2 twice a day, on days 1-5 and 8-12 every 28days. |
| Name | Type | Description |
|---|---|---|
| Irinotecan | DRUG | Irinotecan is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as a "plant alkaloid" and "topoisomerase I inhibitor." |
| Oxaliplatin | DRUG | Oxaliplatin is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Oxaliplatin is classified as an "alkylating agent." |
| TAS 102 (Trifluridine/Tipiracil) | DRUG | Trifluridine/Tipiracil is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor |
Inclusion Criteria: 1. Patients must be 18 years of age or older. 2. Histologically documented locally advanced or metastatic gastric or GEJ adenocarcinoma not previously treated with palliative systemic therapy. 3. Patients must be capable of providing consent to enrolment and treatment. 4. Patien...
TAS 102 is an investigational small molecule being studied for the treatment of gastroesophageal junction adenocarcinoma and advanced gastric carcinoma. It is currently in Phase 2 clinical development for these oncology indications.
TAS 102 is being developed by Avalon GloboCare Corp., a biopharmaceutical company traded on the stock exchange under the ticker symbol ALBT.
TAS 102 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities for any use.
TAS 102 has one completed Phase 2 clinical trial, identified as NCT04808791, titled "iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma." The trial enrolled 7 participants in Canada.
No, the completed Phase 2 trial of TAS 102 was not randomized and did not use a control group. It was an uncontrolled study that enrolled 7 patients with gastroesophageal junction adenocarcinoma or advanced gastric carcinoma.